RPTPγ is known to act as tumour suppressor in various cancers [75], and a recent report has demonstrated that RPTPγ-directed monoclonal antibodies have a potential use as a tool for biomarker detection in chronic myeloid leukaemia (CML) [76]. This evidence concerns the gene PTPRG and neoplasm.